SG11201407842TA - Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide - Google Patents
Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamideInfo
- Publication number
- SG11201407842TA SG11201407842TA SG11201407842TA SG11201407842TA SG11201407842TA SG 11201407842T A SG11201407842T A SG 11201407842TA SG 11201407842T A SG11201407842T A SG 11201407842TA SG 11201407842T A SG11201407842T A SG 11201407842TA SG 11201407842T A SG11201407842T A SG 11201407842TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- isonicotinamide
- phenylamino
- iodo
- dihydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653037P | 2012-05-30 | 2012-05-30 | |
| PCT/EP2013/001352 WO2013178320A1 (en) | 2012-05-30 | 2013-05-07 | Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407842TA true SG11201407842TA (en) | 2014-12-30 |
Family
ID=48537929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407842TA SG11201407842TA (en) | 2012-05-30 | 2013-05-07 | Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9260393B2 (es) |
| EP (1) | EP2855434B1 (es) |
| JP (1) | JP6280543B2 (es) |
| KR (1) | KR20150022923A (es) |
| CN (1) | CN104334530A (es) |
| AR (1) | AR091186A1 (es) |
| AU (1) | AU2013269994B2 (es) |
| BR (1) | BR112014029838A2 (es) |
| CA (1) | CA2875145C (es) |
| CL (1) | CL2014003285A1 (es) |
| DK (1) | DK2855434T3 (es) |
| EA (1) | EA028059B1 (es) |
| ES (1) | ES2592860T3 (es) |
| HK (1) | HK1206733A1 (es) |
| HR (1) | HRP20161135T1 (es) |
| HU (1) | HUE028850T2 (es) |
| IL (1) | IL235947A (es) |
| LT (1) | LT2855434T (es) |
| MX (1) | MX350295B (es) |
| MY (1) | MY169266A (es) |
| NZ (1) | NZ701103A (es) |
| PL (1) | PL2855434T3 (es) |
| PT (1) | PT2855434T (es) |
| RS (1) | RS55167B1 (es) |
| SG (1) | SG11201407842TA (es) |
| SI (1) | SI2855434T1 (es) |
| TW (1) | TWI570108B (es) |
| UA (1) | UA112899C2 (es) |
| WO (1) | WO2013178320A1 (es) |
| ZA (1) | ZA201409426B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015127234A1 (en) * | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
| US10179132B2 (en) | 2015-05-26 | 2019-01-15 | Industry-Academic Cooperation Foundation, Yonsei University | Composition for inducing differentiation of multipotent neural stem cells into dopaminergic neurons and method for inducing differentiation of multipotent neural stem cells into dopaminergic neurons by using the same |
| KR20160138756A (ko) * | 2015-05-26 | 2016-12-06 | 연세대학교 산학협력단 | 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법 |
| SG10202105383QA (en) | 2016-11-25 | 2021-07-29 | Genuv Inc | Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same |
| KR101833412B1 (ko) | 2017-07-24 | 2018-02-28 | 연세대학교 산학협력단 | 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0993437B1 (en) * | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| CA2355374A1 (en) * | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | 1-heterocycle substituted diarylamines |
| CA2482345A1 (en) * | 2002-05-31 | 2003-12-11 | Bayer Pharmaceuticals Corporation | Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
| WO2006045514A1 (en) | 2004-10-20 | 2006-05-04 | Applied Research Systems Ars Holding N.V. | 3-arylamino pyridine derivatives |
| CN102134218A (zh) * | 2009-06-15 | 2011-07-27 | 凯美隆(北京)药业技术有限公司 | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
-
2013
- 2013-05-07 LT LTEP13725913.1T patent/LT2855434T/lt unknown
- 2013-05-07 HU HUE13725913A patent/HUE028850T2/en unknown
- 2013-05-07 AU AU2013269994A patent/AU2013269994B2/en active Active
- 2013-05-07 CA CA2875145A patent/CA2875145C/en active Active
- 2013-05-07 SI SI201330301A patent/SI2855434T1/sl unknown
- 2013-05-07 ES ES13725913.1T patent/ES2592860T3/es active Active
- 2013-05-07 KR KR20147036740A patent/KR20150022923A/ko not_active Application Discontinuation
- 2013-05-07 RS RS20160795A patent/RS55167B1/sr unknown
- 2013-05-07 CN CN201380028114.0A patent/CN104334530A/zh active Pending
- 2013-05-07 SG SG11201407842TA patent/SG11201407842TA/en unknown
- 2013-05-07 EA EA201401341A patent/EA028059B1/ru not_active IP Right Cessation
- 2013-05-07 WO PCT/EP2013/001352 patent/WO2013178320A1/en active Application Filing
- 2013-05-07 MX MX2014014520A patent/MX350295B/es active IP Right Grant
- 2013-05-07 PL PL13725913.1T patent/PL2855434T3/pl unknown
- 2013-05-07 JP JP2015514374A patent/JP6280543B2/ja active Active
- 2013-05-07 NZ NZ701103A patent/NZ701103A/en not_active IP Right Cessation
- 2013-05-07 MY MYPI2014703509A patent/MY169266A/en unknown
- 2013-05-07 BR BR112014029838A patent/BR112014029838A2/pt not_active Application Discontinuation
- 2013-05-07 DK DK13725913.1T patent/DK2855434T3/en active
- 2013-05-07 US US14/404,060 patent/US9260393B2/en active Active
- 2013-05-07 PT PT137259131T patent/PT2855434T/pt unknown
- 2013-05-07 EP EP13725913.1A patent/EP2855434B1/en active Active
- 2013-05-29 TW TW102119003A patent/TWI570108B/zh active
- 2013-05-29 AR ARP130101864 patent/AR091186A1/es unknown
- 2013-07-05 UA UAA201413849A patent/UA112899C2/uk unknown
-
2014
- 2014-11-27 IL IL235947A patent/IL235947A/en not_active IP Right Cessation
- 2014-11-28 CL CL2014003285A patent/CL2014003285A1/es unknown
- 2014-12-19 ZA ZA2014/09426A patent/ZA201409426B/en unknown
-
2015
- 2015-07-30 HK HK15107274.5A patent/HK1206733A1/xx unknown
-
2016
- 2016-09-05 HR HRP20161135TT patent/HRP20161135T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201407596TA (en) | Conjugation reagents | |
| SG11201407898WA (en) | Electrode testing apparatus | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201408303WA (en) | Adhesive compositions of propylene-based and ethylene-based polymers | |
| SG11201408561YA (en) | Tunable materials | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201407402TA (en) | Carbazole-containing sulfonamides as cryptochrome modulators | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201407842TA (en) | Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide | |
| SG11201407801VA (en) | Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201407988UA (en) | Process for improved opioid synthesis | |
| SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
| SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
| SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
| SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation | |
| SG11201406745VA (en) | Methods of therapeutic monitoring of phenylacetic acid prodrugs | |
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors | |
| SG11201901320WA (en) | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction |